Authors: Adenis, A Bonneterre, J Bonneterre, ME Pion, JM Vanlemmens, L Gladieff, L de Lafontan, B Martel, P Mihura, J Roche, H Gedouin, D Kerbrat, P Lesimple, T Bremond, A Devaux, Y Delecroix, V Fumoleau, P Maugard-Louboutin, C Namer, M Goudier, MJ Morice, F Montcuquet, P Schraub, S Coudert, B Fargeot, P de Gislain, C Mayer, F Bastit, P Chevallier, B Grandgirard, A Monnier, A Sun, X Clavere, P Ollivier, JP Rhein, B Roullet, B Datchary, J Audhuy, B Barats, JC Kohser, F Dides, S Ramos, R Cattan, A Eymard, JC Pourny, C Weber, B de Laroche, G Pichon, A Seffert, P Hayat, M Zambon, E Chollet, P Van Praagh, I

Citation: A. Adenis et al., Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French adjuvant study group 05 randomized trial, J CL ONCOL, 19(3), 2001, pp. 602-611